GlassScriptPhysician profile
Douglas Sears
NPI 1720062664
$19,711.29
in general payments reported to CMS, 2019-2025
37 companies · $2,374 in 2025
The $2,374 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $347 · 2021: $4,829 · 2022: $2,730 · 2023: $1,631 · 2024: $6,631 · 2025: $2,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Food and Beverage: $5,105 · Honoraria: $150 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Food and Beverage | $5,104.69 |
| Honoraria | $150.00 |
| Education | $131.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $5,220.07 | 2021-2024 | Aplenzin, Wellbutrin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,002.78 | 2021-2024 | Rexulti |
| Abbvie INC. | $1,904.51 | 2021-2025 | Vraylar, Qulipta |
| Corium, LLC | $1,866.25 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $894.17 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $596.78 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Alkermes, INC. | $505.44 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $437.30 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $432.83 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $342.36 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $335.30 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $304.77 | 2019-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $265.14 | 2019-2025 | Fanapt |
| Allergan, INC. | $244.90 | 2019-2020 | |
| Neos Therapeutics, LP | $239.87 | 2019-2025 | Adzenys Xr-Odt, Exxua |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.